Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Accumulated Expenses (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Accumulated Expenses data on record, last reported at $4.1 million in Q1 2026.

  • On a quarterly basis, Accumulated Expenses rose 101.67% to $4.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $4.1 million, a 101.67% increase, with the full-year FY2025 number at $581761.0, down 78.29% from a year prior.
  • Accumulated Expenses reached $4.1 million in Q1 2026 per IKT's latest filing, up from $581761.0 in the prior quarter.
  • Over the last five years, Accumulated Expenses for IKT hit a ceiling of $4.1 million in Q1 2026 and a floor of $417573.0 in Q3 2022.
  • A 5-year average of $1.9 million and a median of $2.0 million in 2025 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: soared 3461.93% in 2022, then plummeted 78.29% in 2025.
  • Tracing IKT's Accumulated Expenses over 5 years: stood at $459997.0 in 2022, then surged by 391.3% to $2.3 million in 2023, then rose by 18.59% to $2.7 million in 2024, then tumbled by 78.29% to $581761.0 in 2025, then soared by 608.99% to $4.1 million in 2026.
  • Business Quant data shows Accumulated Expenses for IKT at $4.1 million in Q1 2026, $581761.0 in Q4 2025, and $2.1 million in Q3 2025.